The PRETREAT randomized clinical trial demonstrates that proactive, risk-stratified intraoperative blood pressure targets do not reduce six-month functional disability compared to standard care in noncardiac surgery patients, suggesting that higher MAP targets may not translate into long-term functional benefits.